Examination of therapeutic efficacy after changing faricimab for patients with wet age-related macular degeneration using existing anti-VEGF drugs
Not Applicable
Recruiting
- Conditions
- wet age-related macular degeneration
- Registration Number
- JPRN-UMIN000052582
- Lead Sponsor
- kagawa university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas 2) Presence of subretinal hemorrhage, scar or macular fibrosis (>50% lesion area) 3) Prior treatment with dexamethasone (<6 months) or triamcinolone (<30 days), intraocular surgery (<3 months) 4) Active intraocular inflammation 5) Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 6) Patient who the doctor in charge judges are ineligible for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement rate of visual acuity one year after the change of faricimab.
- Secondary Outcome Measures
Name Time Method One year outcome after the change of faricimab:macula dry rate(presence of absence of exudative change), reduction rate of central macular thickness, change rate of subfoveal choroidal thickness, the rate of incidence and enlargement of macular atrophy, and number of administrations